Belleville

Psoriasis is a chronic inflammatory disease that causes thick, red, and white scaly patches on the skin. This research evaluates how treatment with risankizumab affects the quality of life for adults with moderate to severe plaque psoriasis in real-world clinical settings. The study involves about 700 participants who are prescribed risankizumab by their doctors following local guidelines. Participants will receive risankizumab as directed by their physicians according to routine clinical practice and local prescribing information. There are no additional treatments or interventions beyond what is normally prescribed. The study follows participants for up to 2.5 years, with regular visits at hospitals or clinics based on their usual care schedules. During the study, participants will attend routine visits without extra burden. Researchers will monitor changes in quality of life using the Dermatology Life Quality Index (DLQI) at 12 months and observe the long-term impact of risankizumab treatment. Safety and treatment adherence will also be tracked throughout the study period.